Pathomics Signature for Prognosis and CA19‐9 Interception in Pancreatic Ductal Adenocarcinoma: A Real‐Life, Multi‐Center Study

Documenti analoghi

• The Evolutionary Trajectory and Prognostic Value of GITR+ Tregs Reprogramed by Tumor‐Intrinsic PD‐1/c‐MET Signaling in Pancreatic Cancer
  di: Jiande Han, et al.
  Pubblicazione: (2025)
• Ubiquitination‐Associated Ductal–Fibroblast Crosstalk Shapes Tumor Progression and Prognosis in Pancreatic Ductal Adenocarcinoma
  di: Yiping Fu, et al.
  Pubblicazione: (2026)
• The Crosstalk with CXCL10‐Rich Tumor‐Associated Mast Cells Fuels Pancreatic Cancer Progression and Immune Escape
  di: Hanlin Yin, et al.
  Pubblicazione: (2025)
• Neoadjuvant Therapy‐Induced Remodeling in Pancreatic Ductal Adenocarcinoma: Multimodal Spatial Analysis and Prognosis
  di: Xiaofei Zhang, et al.
  Pubblicazione: (2026)
• Aspartame Increases the Risk of Pancreatic Ductal Adenocarcinoma
  di: Jumin Xie, et al.
  Pubblicazione: (2026)